



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) #22

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁵ : C12N 15/37, 7/04, 15/86 C12N 5/10, A61K 39/12 G01N 33/53, C07K 13/00 | A1 | (11) International Publication Number: WO 94/05792 (43) International Publication Date: 17 March 1994 (17.03.94) |
| (21) International Application Number: PCT/US93/08342 (22) International Filing Date: 3 September 1993 (03.09.93) (30) Priority data: 07/941,371 3 September 1992 (03.09.92) US 08/032,869 16 March 1993 (16.03.93) US (71) Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Washington, DC (US). (72) Inventors: LOWY, Douglas, R. ; 3414 Garfield Street, N.W., Washington, DC 20007 (US). SCHILLER, John, T. ; 11306 Maple View Drive, Silver Spring, MD 20902 (US). KIRNBAUER, Reinhard ; 8315 North Brook Lane, #905, Bethesda, MD 20814 (US). | | (74) Agents: ALTMAN, Daniel, E. et al.; Knobbe, Martens, Olson & Bear, 620 Newport Center Drive, Suite 1600, Newport Beach, CA 92660 (US). (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: SELF-ASSEMBLING RECOMBINANT PAPILLOMAVIRUS CAPSID PROTEINS (57) Abstract <p>Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | FR | France | MR | Mauritania |
| AU | Australia | GA | Gabon | MW | Malawi |
| BB | Barbados | GB | United Kingdom | NE | Niger |
| BE | Belgium | GN | Guinea | NL | Netherlands |
| BF | Burkina Faso | GR | Greece | NO | Norway |
| BG | Bulgaria | HU | Hungary | NZ | New Zealand |
| BJ | Benin | IE | Ireland | PL | Poland |
| BR | Brazil | IT | Italy | PT | Portugal |
| BY | Belarus | JP | Japan | RO | Romania |
| CA | Canada | KP | Democratic People's Republic of Korea | RU | Russian Federation |
| CF | Central African Republic | KR | Republic of Korea | SD | Sudan |
| CG | Congo | KZ | Kazakhstan | SE | Sweden |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovak Republic |
| CM | Cameroon | LU | Luxembourg | SN | Senegal |
| CN | China | LV | Latvia | TD | Chad |
| CS | Czechoslovakia | MC | Monaco | TG | Togo |
| CZ | Czech Republic | MG | Madagascar | UA | Ukraine |
| DE | Germany | ML | Mali | US | United States of America |
| DK | Denmark | MN | Mongolia | UZ | Uzbekistan |
| ES | Spain | | | VN | Viet Nam |
| FI | Finland | | | | |

BEST COPY AVAILABLE

SELF-ASSEMBLING RECOMBINANT PAPILLOMAVIRUS CAPSID PROTEINS

Field of the Invention

5 This invention relates to recombinant viral proteins. It relates particularly to recombinant viral proteins that are suitable for use in the diagnosis, prophylaxis and therapy of viral infections.

Background of the Invention

10 Papillomaviruses infect the epithelia of a wide variety of species of animals, including humans, generally inducing benign epithelial and fibro-epithelial tumors, or warts, at the site of infection. Each species of vertebrate is infected by a distinct group of papillomaviruses, each papillomavirus group comprising several papillomavirus types. For example, more than 60 different human papillomavirus (HPV) genotypes have been isolated. Papillomaviruses are highly species specific infective agents; for example, a bovine papillomavirus cannot induce papillomas in a heterologous species, such as humans. Papillomavirus types ALSO appear to be highly specific as immunogens in that a neutralizing immunity to infection against one papillomavirus type does not usually confer immunity against another type, even when the types infect an homologous species.

15 In humans, genital warts, which are caused by human papillomaviruses, represent a sexually transmitted disease. Genital warts are very common, and subclinical, or inapparent HPV infection is even more common than clinical infection. Some benign lesions in humans, particularly those arising from certain papillomavirus types, undergo malignant progression. For that reason, infection by one of the malignancy associated papilloma virus types is considered one of the most significant risk factors in the development of cervical cancer, the second most common cancer of women worldwide (zur Hausen, H., 1991; Schiffman, M. 25 1992). Several different HPV genotypes have been found in cervical cancer, with HPV16 being the most common type that is isolated from 50% of cervical cancers.

 Immunological studies demonstrating the production of neutralizing antibodies to papillomavirus antigens indicate that papillomavirus infections and malignancies associated with these infections in vertebrate animals could be prevented through immunization; however the development of effective papillomavirus vaccines has been impeded by a number of difficulties.

30 First, it has not been possible to generate in vitro the large stocks of infectious virus required to determine the structural and immunogenic features of papillomavirus that are fundamental to the development of effective vaccines. Cultured cells express papillomavirus 35

-2-

oncoproteins and other non-structural proteins and these have been extensively studied in vitro; but expression of the structural viral proteins, L1 and L2 (and the subsequent assembly of infectious virus) occurs only in terminally differentiated layers of infected epithelial tissues. Therefore, the characterization of viral genes, proteins, and structure has necessarily been assembled from studies of virus harvested from papillomas. In particular, papillomavirus structure and related immunity have been carried out in the bovine papillomavirus system because large amounts of infectious virus particles can be isolated from bovine papillomavirus (BPV) warts.

The information derived from studies of papillomavirus structure to date indicates that all papillomaviruses are non-enveloped 50-60 nm icosahedral structures (Crawford, L., et al., 1963) which are comprised of conserved L1 major capsid protein and less well conserved L2 minor capsid protein (Baker, C., 1987). There is no sequence relationship between the two proteins. The function and location of L2 in the capsid is unclear; however immunologic data suggests that most of L2 is internal to L1.

Recently, high resolution cryoelectron microscopic analysis of BPV1 and HPV1 virions has determined that the two viruses have a very similar structure, with 72 pentameric capsomers, each capsomer presumably composed of five L1 molecules, forming a virion shell with T=7 symmetry (Baker, T., 1991). The location of the minor L2 capsid protein in the virion has not been determined, and it is not certain whether L2 or other viral proteins are needed for capsid assembly. Superficially, papillomavirus structure resembles that of the polyoma 45 nm virion, which has the same symmetry and capsomere number (Liddington, R., et al., 1991); however, the systems of intracapsomer contact for polyomavirus and papillomavirus species are different, and the major and minor capsid proteins of polyomavirus are not genetically related to L1 and L2.

Bovine papillomavirus studies are facilitated by a quantitative focal transformation infectivity assay developed for BPV that is not available for HPV (Dvoretzky, I., et al., 1980), and an understanding of immunity to papillomavirus has therefore also been derived from the bovine papillomavirus system. Limited studies using intact bovine papillomavirus demonstrated that the non-cutaneous inoculation of infectious or formalin-inactivated BPV virus was effective as a vaccine to prevent experimental BPV infection in calves (Olson, C., et al., 1960; Jarrett, W., et al., 1990). Unfortunately, BPV virions cannot be used to develop vaccines against papillomavirus which infects other species, or even vaccines against other bovine types, because of the great specificity of these viruses, as well as concern for the oncogenic potential of intact viral particles.

A significant conclusion of studies of papillomavirus immunity is that the ability of antibodies to neutralize papilloma virus appears to be related to their ability to react with type-specific, conformationally dependent epitopes on the virion surface. For example, rabbit antisera raised against infectious BPV1 virions inhibits focal transformation of C127 cells (Doretzky, I., et al., 1980), as well as the transformation of fetal bovine skin grafts; whereas antisera raised against denatured virions does not (Ghim, S., et al., 1991).

In contrast, neutralizing sera generated against bacterially derived BPV L1 and L2 (Pilacinski, W. et al., 1984; Jin, X., et al., 1989) and against in vitro synthesized cottontail rabbit papillomavirus (CRPV) L1 and L2 (Christensen, N., et al., 1991; Lin, Y-L, et al., 1992), neither of which has the structural features of native virions, had low titers, and the use of recombinant HPV L1 fusion peptides expressed in *E. coli* to detect cellular immune reactivity has had only limited success (Höpfl, R. et al., 1991). The results in the BPV system are consistent with those of the HPV system, in which monoclonal antibodies that neutralized HPV11 infection in a mouse xenograft assay recognized native, but not denatured, HPV11 virions (Christensen, N., et al., 1990).

There have been isolated attempts to produce papillomavirus capsids in vitro. Zhou, J. et al. (1991) and (1992) produced virus-like particles by cloning HPV L1 and L2 genes, and HPV L1 and L2 genes in combination with HPV E3/E4 genes into a vaccinia virus vector and infecting CV-1 mammalian cells with the recombinant vaccinia virus. These studies were interpreted by Zhou to establish that expression of HPV16 L1 and L2 proteins in epithelial cells is necessary and sufficient to allow assembly of virion type particles. Cells infected with doubly recombinant vaccinia virus which expressed L1 and L2 proteins showed small (40 nm) virus-like particles in the nucleus that appeared to be incompletely assembled arrays of HPV capsomers. Expressing L1 protein alone, or L2 protein alone, was expressed did not produce virus-like particles; cells doubly infected with singly recombinant vaccinia virus containing L1 and L2 genes also did not produce particles. No neutralizing activity was reported.

Ghim et al., (1992) reported that when L1 from HPV1, a non-genital virus type associated mainly with warts on the hands and feet, was expressed in mammalian cells, the L1 protein contained conformational epitopes found on intact virions. Ghim did not determine if particles were produced, nor was it evaluated if the L1 protein might induce neutralizing antibodies. Even more recently, Hagansee, et al. (1993) reported that when L1 from HPV1 was expressed in human cells, it self-assembled into virus-like particles. No neutralizing antibody studies were performed.

-4-

Studies in other virus systems, for example, parvovirus, indicate that capsid assembly alone may not confer immunogenicity. Parvovirus VP2, by itself, was able to self-assemble when expressed in insect cells, but only particles containing both VP1 and VP2 were able to induce neutralizing antibodies (Kajigaya, S., et al., 1991).

5 It would be advantageous to develop methods for producing renewable papillomavirus reagents of any selected species and type in cell culture. It would also be beneficial to produce such papillomavirus reagents having the immunity conferring properties of the conformed native virus particles that could be used as a subunit vaccine.

10 It is therefore the object of the invention to provide these recombinant conformed papillomavirus proteins, as well as methods for their production and use.

Summary of the Invention

15 The invention is directed to the diagnosis and prevention of papillomavirus infections and their benign and malignant sequelae by providing recombinant papillomavirus capsid proteins that self assemble to form capsomer structures comprising conformational epitopes that are highly specific and highly immunogenic. Therefore, according to the invention there is provided a genetic construct, comprising a papillomavirus L1 conformational coding sequence, inserted into a baculovirus transfer vector, and operatively expressed by a promoter of that vector. The papillomavirus L1 conformational coding sequence can be isolated from a bovine, monkey, or human gene. In a preferred embodiment, the
20 papillomavirus L1 conformational coding sequence is isolated from a wild type HPV16 gene. In a particularly preferred embodiment, the papillomavirus L1 conformational coding sequence is SEQ ID NO:6. The genetic construct can further comprise a papillomavirus L2 coding sequence.

25 According to another aspect of the invention there is provided a non-mammalian eukaryotic host cell transformed by the genetic constructs of the invention.

According to yet another aspect of the invention there is provided a method for producing a recombinant papillomavirus capsid protein, assembled into a capsomer structure or a portion thereof, comprising the steps of (1)
30 cloning a papillomavirus gene that codes for an L1 conformational capsid protein into a transfer vector wherein the open reading frame of said gene is under the control of the promoter of said vector; (2) transferring the recombinant vector into a host cell, wherein the cloned papillomavirus gene expresses the papillomavirus capsid protein; and (3) isolating capsomer structures, comprising the papillomavirus capsid protein, from the host cell. In a preferred embodiment, the cloned papillomavirus gene consists essentially

-5-

of the conformational L1 coding sequence, and the expressed protein assembles into capsomer structures consisting essentially of L1 capsid protein. In another preferred embodiment, the cloning step of the method further comprises the cloning of a papillomavirus gene coding for L2 capsid protein, whereby said L1 and L2 proteins are coexpressed in the host cell, and wherein the isolated capsomer structures comprise L1 and L2 capsid proteins;

provided that said transfer vector is not a vaccinia virus when said host cell is a mammalian cell. The conformational L1 coding sequence can be cloned from a bovine, monkey, or human papillomavirus. According to a preferred embodiment, the conformational L1 coding sequence is cloned from a wild type HPV16 papillomavirus. In a particularly preferred embodiment, the conformational L1 coding sequence is SEQ ID NO:6. Also in a preferred embodiment, the host cell into which the genetic construct is transfected is an insect cell. Also preferred are embodiments wherein the transfer vector is a baculovirus based transfer vector, and the papillomavirus gene is under the control of a promoter that is active in insect cells. Accordingly in this embodiment, the recombinant baculovirus DNA is transfected into Sf-9 insect cells, preferably co-transfected with wild-type baculovirus DNA into Sf-9 insect cells.

In an alternative embodiment of the method of the invention, the transfer vector is a yeast transfer vector, and the recombinant vector is transfected into yeast cells.

According to yet another aspect of the invention there is provided a virus capsomer structure, or a portion thereof, consisting essentially of papillomavirus L1 capsid protein, produced by the method the invention. Alternatively, the virus capsomer structure can consist essentially of papillomavirus L1 and L2 capsid proteins, produced by the method of the invention. In a particularly preferred embodiment, the virus capsomer structure comprises papillomavirus L1 capsid protein that is the expression product of an HPV16 L1 DNA cloned from a wild type virus.

The virus capsids or capsomer structures of the invention, or portions or fragments thereof, can consist essentially of papillomavirus L1 capsid protein. Alternatively, these capsids or capsomer structures or their fragments can consist essentially of wild type HPV16 papillomavirus L1 capsid protein.

The virus capsid structures according to any of the methods of the invention comprise capsid proteins having immunogenic conformational epitopes capable of inducing neutralizing antibodies against native papillomavirus. The capsid proteins can be bovine, monkey or human papillomavirus L1 proteins. In a preferred embodiment, the

papillomavirus L1 capsid protein is the expression product of a wild type HPV16 L1 gene. In a particularly preferred embodiment, the HPV16 L1 gene comprises the sequence of SEQ ID NO:6.

5 According to yet another aspect of the invention there is provided a unit dose of a vaccine, comprising a peptide having conformational epitopes of a papillomavirus L1 capsid protein, or L1 protein and L2 capsid proteins, in an effective immunogenic concentration sufficient to induce a papillomavirus neutralizing antibody titer of at least about 10^3 when administered according to an immunizing dosage schedule. In a preferred embodiment, the vaccine comprises an L1 capsid protein which is an HPV16 capsid protein. In a particularly preferred embodiment, the vaccine comprises an L1 capsid protein that is a wild type HPV16 L1 protein.

10 Use of the L1 open reading frame (ORF) from a wild type HPV16 papillomavirus genome, according to the methods of the invention, particularly facilitates the production of preparative amounts of virus-like particles on a scale suitable for vaccine use.

15 According to yet another aspect of the invention, there is provided a method of preventing or treating papillomavirus infection in a vertebrate, comprising the administration of a papillomavirus capsomer structure or a fragment thereof according to the invention to a vertebrate, according to an immunity-producing regimen. In a preferred embodiment, the papillomavirus capsomer structure comprises wild type HPV16 L1 capsid protein.

20 The invention further provides a method of preventing or treating papillomavirus infection in a vertebrate, comprising the administration of the papillomavirus capsomer structure of the invention, or a vaccine product comprising the capsomer structure to a vertebrate, according to an immunity-producing regimen. In a preferred embodiment, the papillomavirus vaccine comprises wild type HPV16 L1 capsid protein.

25 Also within the scope of the invention is a method for immunizing a vertebrate against papillomavirus infection, comprising administering to the vertebrate a recombinant genetic construct of the invention comprising a conformational papillomavirus L1 coding sequence, and allowing said coding sequence to be expressed in the cells or tissues of said vertebrate, whereby an effective, neutralizing, immune response to papillomavirus is induced.

30 In a preferred embodiment, the conformational papillomavirus L1 coding sequence is derived from human papillomavirus HPV16. In a particularly preferred embodiment, the human papillomavirus HPV16 is a wild type papillomavirus.

According to yet another aspect of the invention, there is provided a method of detecting humoral immunity to papillomavirus infection in a vertebrate comprising the steps

-7-

of: (a) providing an effective antibody-detecting amount of a papillomavirus capsid peptide having at least one conformational epitope of a papillomavirus capsomer structure; (b) contacting the peptide of step (a) with a sample of bodily fluid from a vertebrate to be examined for papillomavirus infection, and allowing papillomavirus antibodies contained in said sample to bind thereto, forming antigen-antibody complexes; (c) separating said complexes from unbound substances; (d) contacting the complexes of step (c) with a detectably labelled immunoglobulin-binding agent; and (e) detecting anti-papillomavirus antibodies in said sample by means of the labelled immunoglobulin-binding agent that binds to said complexes. In a preferred embodiment of this aspect of the invention, the peptide consists essentially of papillomavirus L1 capsid protein. According to an alternative embodiment, the peptide consists essentially of the expression product of a human papillomavirus HPV16. In a particularly preferred embodiment, the peptide consists essentially of the expression product of a wild type human papillomavirus HPV16 gene, for example, the peptide can consist essentially of the expression product of SEQ ID NO:6.

According to yet another aspect of the invention, there is provided a method of detecting papillomavirus in a specimen from an animal suspected of being infected with said virus, comprising contacting the specimen with antibodies having a specificity to one or more conformational epitopes of the capsid of said papillomavirus, wherein the antibodies have a detectable signal producing label, or are attached to a detectably labelled reagent; allowing the antibodies to bind to the papillomavirus; and determining the presence of papillomavirus present in the specimen by means of the detectable label.

According to yet another aspect of the invention, there is provided a method of determining a cellular immune response to papillomavirus in an animal suspected of being infected with the virus, comprising contacting immunocompetent cells of said animal with a recombinant wild type papillomavirus L1 capsid protein, or combined recombinant L1 and L2 capsid proteins according to the invention; and assessing cellular immunity to papillomavirus by means of the proliferative response of said cells to the capsid protein. In a preferred embodiment of this aspect of the invention, the recombinant papillomavirus protein is introduced into the skin of the animal.

According to yet another aspect of the invention there is provided a papillomavirus infection diagnostic kit, comprising capsomer structures consisting essentially of papillomavirus L1 capsid protein, or capsomer structures comprising papillomavirus L1 protein and L2 capsid proteins, or antibodies to either of these capsomer structures, singly

or in combination, together with materials for carrying out an assay for humoral or cellular immunity against papillomavirus, in a unit package container.

Detailed Description of the Invention

We have discovered that the gene coding for the L1 major capsid protein of BPV or HPV16, following introduction into host cells by means of an appropriate transfer vector, can express L1 at high levels, and that the recombinant L1 has the intrinsic capacity to self-assemble into empty capsomer structures that closely resemble those of an intact virion.

Further, the self-assembled recombinant L1 capsid protein of the invention, in contrast to L1 protein extracted from recombinant bacteria, or denatured virions, has the efficacy of intact papillomavirus particles in the ability to induce high levels of neutralizing antiserum that can protect against papillomavirus infection. The high level of immunogenicity of the capsid proteins of the invention implies strong antibody binding properties that make them sensitive agents in serological screening tests to detect and measure antibodies to conformational virion epitopes. Their immunogenicity also indicates that the capsid proteins of the invention can also be used as highly effective vaccines or immunogens to elicit neutralizing antibodies to protect a host animal against infection by papillomavirus. These observations were recently published in Kirnbauer, et al., (1992), and formed the basis of U.S. application Serial No. 07/941,371.

We have now discovered that the capsid protein L1 expressed by wild type HPV16 genomes isolated from benign papillomavirus lesions, when expressed in the baculovirus system described, will self-assemble with an efficiency heretofore unknown and comparable to that of bovine papillovirus L1 capsid protein.

The HPV16 L1 Gene Sequence

The source of HPV16 L1 DNA, as disclosed in published studies, for example, by Zhou, et al.(1991) was the prototype clone, GenBank Accession No. K02718, that had been isolated from a cervical carcinoma (Seedorf, et al., 1985). We have found that L1 from wild type HPV16 genome, which differs from the prototype genome by a single point mutation, will self-assemble into virus-like particles with an efficiency similar to that seen with BPV L1 or BPV L1/L2. Compared with the self-assembly seen when L1 from the prototype HPV genome is used with L2, L1 from a wild-type genome self-assembles at least 100 times more efficiently.

To provide genetic insight into the self-assembly efficiency of different HPV16 L1 expression products, the open reading frames from HPV16 L1 genes isolated from both benign lesions and lesions associated with dysplasia or carcinoma were sequenced.

-9-

The analysis detected two errors in the published sequence of the published L1 sequence of the prototype strain, as follows:

- (1) there should be an insertion of three nucleotides (ATC) between nt 6902 and 6903, which results in the insertion of a serine in the L1 protein; and
- (2) there should be a deletion in the published prototype sequence of three nucleotides (GAT), consisting of nt 6952-6954, which deletes an aspartate from the L1 protein sequence. The corrected nucleotide sequence of the prototype HPV16 L1 genome, consisting of nt 5637-7155, is that of SEQ ID NO:5, listed herein.

The numbering of the nucleotide bases in Sequence ID Nos. 5 and 6 is indexed to 1, and the numbering of nucleotide bases of the published HPV sequence, that is from nt 5638-7156, corresponds to those of the sequence listing from 1-1518. The sites referred to in the original sequence can be thus readily identified by one skilled in the art.

Three other HPV16 L1 genomes, clone 16PAT; and clones 114/16/2 and 114/16/11, were sequenced and those sequences compared to that of the corrected prototype.

Clone 16PAT, kindly provided by Dennis McCance at the University of Rochester School of Medicine, and cloned from a dysplastic (pre-malignant) lesion of the cervix, expresses an L1 that does not self-assemble efficiently.

Clones 114/16/2 and 114/16/11, kindly provided by Matthias Dürst of the German Cancer Research Center in Heidelberg, were both cloned from non-malignant lesions, and both expressed L1 protein that self-assembled efficiently.

Comparison of Genetic Characteristics of HPV16 L1 associated with Dysplasia, Malignant Progression and Benign Lesions

Clone 16PAT, isolated from papillomavirus infected dysplastic lesions and the prototype HPV16, isolated from malignant cervical carcinoma, both encode Histidine at nt 6242-6244, while clones 2 and 11, isolated from benign papillomavirus infected lesions (like isolates of many other papillomavirus) encode Aspartate at this site.

It appears that this single amino acid difference between the prototype, malignancy-associated HPV16 species, and the HPV16 species from benign lesions accounts for the difference in self-assembly efficiency. It is likely that among closely related HPV types, Aspartate at this locus may be necessary for efficient self-assembly, and that the substitution of Histidine for Aspartate impairs this ability in the capsid protein. The impairment in capsid assembly in malignancy-associated viruses, associated with loss of the conformational

-10-

epitopes required for the production of neutralizing antibodies, may also be linked to a lowered immunogenicity which would allow the papillomavirus to escape immune control.

Accordingly, HPV16 L1 genes that express capsid protein that self-assembles efficiently can be obtained by

- 5 (1) isolation of the wild type HPV16 L1 open reading frame from benign lesions of papillomavirus infection; or
- (2) carrying out a site specific mutation in the prototype sequence at nt 6242-6244 to encode Aspartate.

Recombinant Capsid Protein

10 The method of the invention provides a means of preparing recombinant capsid particles for any papillomavirus. Particles consisting of either L1 or L2 capsid protein alone, or consisting of both L1 and L2 capsid proteins together can be prepared. L1/L2 capsid protein particles are more closely related to the composition of native papillomavirus virions, but L2 does not appear to be as significant as L1 in conferring immunity, probably
15 because most of L2 is internal to L1 in the capsid structure. Although L1 can self-assemble by itself, in the absence of L2, self-assembled L1/L2 capsid protein particles are more closely related to the composition of native papillomavirus virions. Accordingly, particles comprising L1 alone are simpler, while those comprising L1/L2 may have an even more authentic structure. Both self-assembled L1 and L1/L2 particles induce high-titer
20 neutralizing antibodies and may therefore be suitable for vaccine production. Particles comprising L1 capsid protein expressed by a wild type HPV genome, either as L1 alone or L1/L2 together, are particularly preferred.

Production of the recombinant L1, or combined L1/L2, capsid particles is carried out by cloning the L1 (or L1 and L2) gene(s) into a suitable vector and expressing the
25 corresponding conformational coding sequences for these proteins in a eukaryotic cell transformed by the vector. It is believed that the ability to form a capsid-like structure is intimately related to the ability of the capsid protein to generate high-titer neutralizing antibody, and that in order to produce a capsid protein that is capable of self-assembling into capsid structures having conformational epitopes, substantially all of the capsid protein coding sequence must be expressed. Accordingly, substantially all of the capsid protein
30 coding sequence is cloned. The gene is preferably expressed in a eukaryotic cell system. Insect cells are preferred host cells; however, yeast cells are also suitable as host cells if appropriate yeast expression vectors are used. Mammalian cells similarly transfected using appropriate mammalian expression vectors can also be used to produce assembled capsid

-11-

protein, however, cultured mammalian cells are less advantageous because they are more likely than non-mammalian cells to harbor occult viruses which might be infectious for mammals.

According to a preferred protocol, a baculovirus system is used. The gene to be cloned, substantially all of the coding sequence for bovine papillomavirus (BPV1) or human papillomavirus (HPV16) L1 capsid protein, or human papillomavirus HPV16 L1 and L2, is inserted into a baculovirus transfer vector containing flanking baculovirus sequences to form a gene construct, and the recombinant DNA is co-transfected with wild type baculovirus DNA into Sf-9 insect cells as described in Example 1, to generate recombinant virus which, on infection, can express the inserted gene at high levels. The actual production of protein is made by infecting fresh insect cells with the recombinant baculovirus; accordingly, the L1 capsid protein and the L1 and L2 capsid proteins are expressed in insect cells that have been infected with recombinant baculovirus as described in Example 2.

In the procedure of Example 1, the complete L1 gene of BPV1 was amplified by polymerase chain reaction (PCR; Saiki, R., et al., 1987) and cloned into AcMNPV (*Autographa californica* nuclear polyhedrosis virus) based baculovirus vector (Summers, M. et al., 1987). The L1 open reading frame was put under the control of the baculovirus polyhedrin promoter. After co-transfection of the L1 clone with the wild type (wt) baculovirus DNA into Sf-9 insect cells (ATCC Accession No. CRL 1711) and plaque purification of recombinant clones, high titer recombinant virus was generated. Extracts from cells infected with wt AcMNPV or BPV1 L1 recombinant viruses (AcBPV-L1) (Example 2) were analyzed by polyacrylamide gel electrophoresis. After Coomassie blue staining, a unique protein of the predicted size, 55 kilodaltons, was detected in extracts from the cultures infected with the AcBPV1-L1 virus. The identity of this protein as BPV L1 was verified by immunoblotting, using a BPV L1 specific monoclonal antibody (Nakai, Y., et al., 1986). Thus, the expression of BPV L1 by means of recombinant virus were demonstrated by SDS-PAGE analysis of lysates from infected insect cells.

To test the hypothesis that papillomavirus L1 has the ability to self-assemble into virus-like particles when overexpressed in heterologous cells, electron micrographs of thin sections from AcBPV-L1 infected cells were examined for the presence of papillomavirus-like structures. Cells infected with the BPV recombinant virus contained many circular structures of approximately 50 nm which were preferentially localized in the nucleus; these structures were absent from wild type baculovirus infected cells. These results suggested that self assembly of L1 into virus-like particles had occurred, since in vivo papillomavirus

-12-

virion assembly takes place in the nucleus and the diameter of the virions has been reported as 55 nm.

Following expression of the conformed capsid protein in the host cell, virus particles are purified from lysates of infected cells as described in Example 4. To obtain further evidence that the L1 protein had self-assembled, virus-like particles were isolated from the infected insect cells by means of gradient centrifugation. We demonstrated the conformation of purified recombinant BPV L1 and HPV16 L1 capsid proteins by electron microscopy, compared with authentic BPV virions.

High molecular mass structures were separated from lysates of L1 recombinant or wild type infected cells by centrifugation through a 40% sucrose cushion and the pelleted material was subjected to CsCl density gradient centrifugation. Fractions were collected and tested for reactivity to the BPV L1 specific monoclonal antibody by immunoblotting.

L1 positive fractions from the gradient were adsorbed onto carbon film grids, stained with 1% uranyl acetate and examined by transmission electron microscopy. In electron microscopy, the positive fractions contained numerous circular structures that exhibited a regular array of capsomers. Consistent with previous reports of the density of empty BPV virions (Larsen, P., et al., 1987), the density of the CsCl fraction containing the peak of the virus-like particles was approximately 1.30 gm/ml. Most were approximately 50 nm in diameter, although smaller circles and partially assembled structures were also seen. In electron microscopy, the larger particles were very similar in size and subunit structure to infectious BPV virions that had been stained and photographed concurrently. These particles were not observed in preparations from mock infected or wt AcMNPV infected cells. These results indicate that BPV L1 has the intrinsic capacity to assemble into virus-like particles in the absence of L2 or other papillomavirus proteins. In addition, specific factors limited to differentiating epithelia or mammalian cells are not required for papillomavirus capsid assembly.

To determine if the ability to self-assemble in insect cells is a general feature of papillomavirus L1, we also expressed the L1 of HPV16, the HPV type most often detected in human genital cancers, via an analogous recombinant baculovirus. A protein of the expected 58 kd size was expressed at high levels in the insect cells infected with the HPV16-L1 recombinant virus, as demonstrated by SDS-PAGE. This protein reacted strongly with an HPV16 L1 monoclonal antibody upon immunoblotting. The monoclonal antibody also lightly stained five other bands ranging in apparent molecular weight from approximately 28 kd to approximately 48 kd. The antibody also reacted weakly with BPV L1, thus this

-13-

antibody lightly stained the 55 kd protein of BPV L1 on the same immunoblot. After CsCl gradient purification, immunoreactive fractions were examined by electron microscopy and found to contain 50 nm papillomavirus-like particles upon electron microscopy. Although somewhat fewer completely assembled particles were seen in the human system in comparison to the BPV L1 preparations, possibly due to the lower levels of expression or greater extent of HPV16 L1 degradation seen in SDS-PAGE, the results conclusively indicate that the L1 of the HPV16 and presumably the L1 proteins of other types, have the intrinsic capacity to assemble into virion-type structures. Preparations of recombinant papillomavirus capsid particles for Rhesus monkey PV have also been carried out as described in the Examples.

Recombinant Conformed Capsid Proteins as Immunogens

Subunit vaccines, based on self-assembled major capsid proteins synthesized in heterologous cells, have been proved effective in preventing infections by several pathogenic viruses, including human hepatitis B (Stevens, C., et al., 1987).

Studies demonstrating that infectious or formalin inactivated BPV is effective as a vaccine, while BPV transformed cells are ineffective, suggest that viral capsid proteins, rather than early gene products, elicit the immune response. Other data in the scientific literature indicates that L1 protein extracted from bacteria was partially successful in eliciting an immune response despite the low titers of neutralizing antibodies. Accordingly, the BPV L1 that was expressed and assembled into virus-like particles in insect cells was studied for its ability to induce neutralizing antisera in rabbits. Two types of preparations were tested: whole cell extracts of L1 recombinant or wild type infected Sf-9 cells and partially purified particles isolated by differential centrifugation and ammonium sulfate precipitation. Following a primary inoculation, the rabbits received two biweekly booster inoculations.

The rabbit sera were tested for the ability to inhibit BPV infection of mouse C127 cells, as measured by a reduction in the number of foci induced by a standard amount of BPV virus. A representative assay was conducted in which the titers of neutralizing antisera induced in animals inoculated with recombinant BPV L1 was compared to antisera against intact and denatured BPV virions. The immune sera generated by inoculation with baculovirus derived L1 were able to reduce the infectivity of the BPV virus by 50% at a dilution of at least 1:11,000 (a titer of 11,000; Table 1), whereas the preimmune sera from the same rabbits did not inhibit focal transformation at a dilution of 1:20, the lowest dilution tested. Both the crude preparations and partially purified particles were effective in

-14-

inducing high titer neutralizing antisera, with 290,000 being the highest titer measured. This was the same as the neutralizing titer of the positive control antiserum raised against infectious BPV virions. In comparison, the highest titer generated in a previous study using bacterially derived L1 was 36 (Pilancinski, W., et al., 1984). The serum from the rabbit inoculated with the extract from the wild type baculovirus infected cells was unable to inhibit infectivity at a dilution of 1:20, indicating that the neutralizing activity was L1 specific. Disruption of the partially purified L1 particles, by boiling in 1% SDS, abolished the ability of the preparation to induce neutralizing antibodies (Table 1). The demonstration that L1 can self-assemble into virion-like particles that elicit neutralizing antisera titers at least three orders of magnitude higher than previous in vitro-produced antigens suggests the recombinant L1 capsid proteins has the potential to induce effective long term protection against naturally transmitted papillomavirus. In view of these results, it appears that the L1 particles assembled in insect cells mimic infectious virus in the presentation of conformationally dependent immunodominant epitopes. These results also establish that L2 is not required for the generation of high titer neutralizing antibodies. The reported weak neutralizing immunogenicity of bacterially derived L1 may occur because it does not assume an appropriate conformation or has not assembled into virion like structures. Also, multiple electrophoretic variants of L1 have been detected in virions (Larsen, P., et al., 1987). Some of these modified species, which are probably absent in the bacterially derived L1, may facilitate the generation of neutralizing antibodies.

The ability of recombinant L1 (or L2) papillomavirus capsid proteins such as those disclosed herein to induce high titer neutralizing antiserum makes them suitable for use as vaccines for prophylaxis against communicable papillomatosis. Examples of populations at risk that could benefit from immunization are bovine herds, which are susceptible to papilloma warts; all humans for non-genital types of HPV infection; and sexually active humans for genital HPV types of infection.

Therapeutic vaccination can be useful for productive papillomavirus lesions, which usually express L1 (and L2) capsid proteins. Such lesions are most likely to occur in benign infections, such as warts or laryngeal papillomatosis. Laryngeal papillomatosis in newborns is usually contracted by the infant during passage through the birth canal where infectious papillomavirus is present in vaginal secretions. Therapeutic vaccination of infected pregnant women against the papillomavirus can induce neutralizing IgG antibody capable of passing through the placental barrier and into the circulation of the fetus to provide prophylactic passive immunity in the infant against this type of papillomavirus infection. Additional

-15-

infant-protecting mechanisms are provided by maternal IgA which is secreted into the vaginal fluid and into breast milk. Jarrett (1991) demonstrates some therapeutic efficacy for L2 in treating BPV-induced warts. Malignant tumors typically do not express L1 or L2, and the efficacy of vaccination with recombinant L1 or L2 in conditions such as cervical cancer, is uncertain.

Protective immunity against both benign and malignant papillomavirus disease can be induced by administering an effective amount of recombinant L1 capsid protein to an individual at risk for papillomavirus infection. A vaccine comprising the capsid protein can be directly administered, either parenterally or locally, according to conventional immunization protocols. In an alternative embodiment, the conformational coding sequence of L1 can be cloned into a transfer vector, for example, a semliki forest virus vector (which produces a mild transient infection), the recombinant virus introduced into the cells or tissues of the recipient where the immunizing capsid protein is then expressed. Vaccinia virus can also be used as a vehicle for the gene.

Recombinant Conformed Capsid Proteins as Serological Screening Agents

Published serologic studies of human immune response to papillomavirus virion proteins have principally utilized bacterially derived L1 and L2 capsid proteins, and the results have not correlated well with other measures of HPV infection (Jenison, S., et al., 1990). BPV papillomavirus immunity studies described above indicate that papillomavirus virion proteins extracted from bacteria do not present the conformationally dependent epitopes that appear to be type-specific and recognized by most neutralizing antibodies. Compared with such assays that primarily recognize linear epitopes, a serological test using self-assembled L1 particles is likely to be a more accurate measure of the extent of anti-HPV virion immunity in the human population. The recombinant L1 capsid proteins disclosed herein, presenting conformational epitopes, can therefore be used as highly specific diagnostic reagents to detect immunity conferring neutralizing antibody to papilloma virus in binding assays of several types. The procedures can be carried out generally as either solid phase or solution assays that provide a means to detect antibodies in bodily fluids that specifically bind to the capsid protein in antigen-antibody pairs. Examples of procedures known to those skilled in the art for evaluating circulating antibodies are solution phase assays, such as double-antibody radioimmunoassays or enzyme immunoassays, or solid phase assays such as strip radioimmunoassay based on Western blotting or an enzyme-linked immunoabsorbent assay (ELISA) as disclosed in U.S. Patent No. 4,520,113 to Gallo et al.

-16-

or immunochromatographic assays as disclosed in U.S. Patent No. 5,039,607 to Skold et al. A preferred ELISA method for the detection of antibodies is that disclosed in Harlow, E. and Lane, D. in Antibodies: A Laboratory Manual Cold Spring Harbor, NY, 1988, pp. 563-578.

5 The recombinant L1 or L1/L2 capsid proteins disclosed herein can also be used to measure cellular immunity to papillomavirus by means of in vivo or in vitro assays, for example, antigen-induced T-cell proliferative responses as described by Bradley, L., 1980, and particularly cellular responses to viral antigens, as described in U.S. Patent No. 5,081,029 to Starling. Cellular immunity to papillomavirus can also be determined by the
10 classical in vivo delayed hypersensitivity skin test as described by Stites, D., 1980; or in a preferred method, according to Höpfel, R., et al., 1991, by the intradermal injection of recombinant HPV L1 fusion proteins.

 The capsid proteins of the invention can also be used as immunogens to raise polyclonal or monoclonal antibodies, according to methods well known in the art. These
15 papillomavirus-specific antibodies, particularly in combination with labelled second antibodies, specific for a class or species of antibodies, can be used diagnostically according to various conventional assay procedures, such as immunohistochemistry, to detect the presence of capsid proteins in samples of body tissue or bodily fluids.

 The genetic manipulations described below are disclosed in terms of their general
20 application to the preparation of elements of the genetic regulatory unit of the invention. Occasionally, the procedure may not be applicable as described to each recombinant molecule included within the disclosed scope. The situations for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the operations can be successfully performed by conventional modifications known to those skilled in the art,
25 e.g. by choice of an appropriate alternative restriction enzyme, by changing to alternative conventional reagents, or by routine modification of reaction conditions. Alternatively, other procedures disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding recombinant molecules of the invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials. In the
30 following examples, all temperatures are set forth in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight.

 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the invention to its fullest extent. The following preferred

-17-

embodiments are therefore to be construed as merely illustrative and not limiting the remainder of the disclosure in any way whatsoever.

EXAMPLE 1

5 Full length L1, or L1 and L2 open reading frames (ORF) were amplified by PCR using the cloned prototypes of BPV1 DNA (Chen, E., et al., 1982), GenBank Accession No. X02346 or HPV16 DNA (Seedorf, K., et al., 1985), GenBank Accession No. K02718; or wild type HPV16 DNA SEQ ID NO:2) as templates. Unique restriction sites were incorporated into the oligonucleotide primers (underlined).

10 BPV1-L1 primer sequence SEQ ID NO:3):

5'-CCGCTGAATTC AATATGGCGTTGTGGCAACAAGGCCAGAAGCTGTAT-3' (sense) and SEQ ID NO:4):

5'-GCGGTGGTACCGTGCAGTTGACTTACCTTCTGTTTTACATTTACAGA-3' (antisense);

15 HPV16-L1 primer sequence SEQ ID NO:5):

5'-CCGCTAGATCTAATATGTCTCTTTGGCTGCCTAGTGAGGCC-3' (sense); and SEQ ID NO:6):

5'-GCGGTAGATCTACACTAATTCAACATACATAACAATACTTACAGC-3' (antisense).

20 L1 coding sequences begin at the 1st methionine codon (bold) for BPV1 and the 2nd methionine for HPV16. BPV1-L1 was cloned as a 5'-EcoRI to 3'-KpnI fragment and HPV16-L1 as a 5'-BglII to 3'-BglII fragment into the multiple cloning site downstream of the polyhedrin promoter of the AcMNPV based baculovirus transfer vector pEV mod (Wang, X., et al. 1991) and verified by sequencing through the AcMNPV/L1 junction. A quantity of 2 µg of CsCl-purified recombinant plasmid was cotransfected with 1 µg wild type

25 AcMNPV DNA (Invitrogen, San Diego, California) into Sf-9 cells (ATCC) using lipofectin (Gibco/BRL, Gaithersburg, Maryland) (Hartig, P., et al., 1991) and the recombinant baculoviruses plaque-purified as described (Summers, M., et al., 1987).

EXAMPLE 2

30 Expression of L1 Proteins or L1/L2 proteins in Insect Cells

Sf-9 cells were either mock infected (mock) or infected at a multiplicity of infection of 10 with either wt AcMNPV (wt) or AcBPV-L1 (B-L1), AcHPV16-L1 (16-L1), or AcHPV16-L1 (16-L1) and AcHPV16-L2 (16-L2) recombinant virus. After 72 hours, cells were lysed by boiling in Laemmli buffer and the lysates subjected to SDS-PAGE in 10%

-18-

gels. Proteins were either stained with 0.25% Coomassie blue or immunoblotted and probed with BPV L1 mAb AU-1 (Nakai, Y., et al., 1986), or HPV16L1 mAb CAMVIR-1 (McLean, C., et al., 1990) and ^{125}I -labeled Fab anti-mouse IgG (Amersham). P designates polyhedrin protein. The anti BPV L1 mAb recognized the expected 55 kd protein. The anti-HPV16L1 mAb strongly stained the expected 58 kd protein, as well as lightly staining five lower molecular weight bands, as discussed above. As also discussed above, this anti-HPV16L1 lightly cross-reacted with the BPV L1 protein.

EXAMPLE 3

Production of antisera

Rabbits were immunized by subcutaneous injection either with whole cell Sf-9 lysates (3×10^7 cells) prepared by one freeze/thaw cycle and 20x dounce homogenization (rabbit #1,2, and 8) or with 200 μg of L1 protein partially purified by differential centrifugation and 35% ammonium sulfate precipitation (#3,4,6, and 7), in complete Freund's adjuvant, and then boosted twice at two week intervals, using the same preparations in incomplete Freund's adjuvant.

EXAMPLE 4

Purification of Particles and Transmission Electron Microscopic (EMK) Analysis

500 ml of Sf-9 cells ($2 \times 10^6/\text{ml}$) were infected with AcBPV-L1 or AcHPV16-L1 or AcHPV16-L1/L2 (16-L1/L2) recombinant baculoviruses. After 72 hr, the harvested cells were sonicated in PBS for 60 sec. After low speed clarification, the lysates were subjected to centrifugation at 110,000g for 2.5 hr through a 40% (wt/vol) sucrose/PBS cushion (SW-28). The resuspended pellets were centrifuged to equilibrium at 141,000g for 20 hr at room temperature in a 10-40% (wt/wt) CsCl /PBS gradient. Fractions were harvested from the bottom and analyzed by SDS-PAGE. Immunoreactive fractions were dialyzed against PBS, concentrated by Centricon 30 (Millipore) ultrafiltration, and (for HPV16-L1) pelleted by centrifugation for 10 min at 30 psi in a A-100 rotor in an airfuge (Beckman). BPV1 virions (Fig. 2B) were purified from a bovine wart (generously provided by A.B. Jensen) as described (Cowser, L., et al., 1987). Purified particles were adsorbed to carbon coated TEM grids, stained with 1% uranyl acetate and examined with a Philips electron microscope EM 400T at 36,000x magnification. Results were obtained by electron microscopy, and are discussed above.

-19-
EXAMPLE 5

BPV1 neutralization assay

Serial dilutions of sera obtained 3 wk after the second boost were incubated with approximately 500 focus forming units of BPV1 virus for 30 min, the virus absorbed to C127 cells for 1 hr and the cells cultured for 3 weeks (Dvoretzky, I., et al., 1980). The foci were stained with 0.5% methylene blue/0.25% carbol fuchsin/methanol. The results were obtained by evaluating the number of foci; these results are discussed below. Anti-AcBPV-L1 was obtained from rabbit #1 and anti-wt AcMNPV from rabbit #8 (Table 1). Preimmune sera at 1:400 dilution was used as a standard. Anti-AcBPV-L1 at either 1:400 or 1:600 dilution substantially eliminated foci, whereas anti-wt AcMNPV at either 1:400 or 1:600 dilution appeared to produce an increase in the number of foci. The normal rabbit serum negative control designated "nrs" at 1:00 dilution was used as a standard for the anti-BPV-1 virion, which appeared to substantially eliminate foci at either 1:400 or 1:600 dilution. The anti-BPV-1 virion was raised against native BPV virions in a previous study (Nakai, Y., et al., 1986). Finally, Dako is the commercially available (Dako Corp., Santa Barbara, California) rabbit antiserum raised against denatured BPV virions. This serum produced a large number of foci, apparently greater than a no Ab control. As a negative control, a no virus test produced substantially no foci.

EXAMPLE 6

Serum Neutralizing Titer against BPV1

Assays were carried out as in Example 5. Rabbits #1, 2, and 8 were inoculated with crude whole cell Sf-9 lysates, and rabbits # 3,4,6, and 7 with partially purified L1 protein (Table 1). Rabbits #6 and 7 were immunized with L1 protein preparations that had been denatured by boiling in 1% SDS. At least two bleeds, taken 3-6 weeks after the second boost, were tested for each rabbit and found to have the same titer. The titer of the preimmune sera from each of the rabbits was less than 20, the lowest dilution tested.

-20-
TABLE 1

| Antigen | rabbit | serum neutralization titer against BPV1* |
|---------------|--------|---|
| AcBPV-L1 | 1 | 11,000 |
| " | 2 | 97,000 |
| " | 3 | 290,000 |
| " | 4 | 97,000 |
| BPV1-virions† | 5 | 290,000 |
| AcBPV-L1/SDS | 6 | <2 |
| " | 7 | <2 |
| wt AcMNPV | 8 | <20 |

*reciprocal of dilution that caused 50% focus reduction

†provided by A.B. Jenson (Nakai, Y., et al., 1986).

-21-
BIBLIOGRAPHY

- U.S. Patent No. 5,081,029 to Starling et al.
- 5 U.S. Patent No. 5,039,607 to Skold et al.
- U.S. Patent No. 4,520,113 to Gallo et al.
- 10 Baker, C. in The Papovaviridae: Vol.2. The Papillomaviruses (N. Salzman et al., eds.) Plenum Press, New York, 1987. p.321.
- Baker, T., et al. Biophys. J. 60:1445 (1991).
- 15 Bradley, L. et al. in Selected Methods in Cellular Immunology. B. Mishell and S. Shügi, eds. San Francisco: W.H. Freeman and Co., 1980. pp. 164-166.
- Christensen, N., et al. Virology 64:5678 (1990).
- Christensen, N., et al. Virology 181:572 (1991).
- 20 Crawford, L., et al. Virology 21:258 (1963).
- Dvoretzky, I., et al. Virology 103:369 (1980).
- 25 Ghim, S., et al. Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int. J. Cancer 49: 285 (1991).
- Ghim, S., et al. HPV1-L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 190:548-552 (1992).
- 30 Hagensee, M., et al. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. of Virology 67(1):315-322.
- 35 Höpfl, R., et al. Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia. Lancet 337:373 (1991).
- Jarrett, W., et al. Veterinary Record 126:449 (1990).
- 40 Jarrett, W., et al. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 184:33 (1991).
- Jenison, S., et al. J. Infectious Dis. 162:60 (1990).
- 45 Jenson, A., et al. Identification of linear epitopes BPV-1 L1 protein recognized by sera of infected or immunized animals. Pathobiology 59:396 (1991).
- Jin, X., et al. J. Gen. Virology 70:1133 (1989).
- 50 Kajigaya, S., et al. Proc. Natl. Acad. Sci. USA 88:4646 (1991).

-22-

Kirnbauer, R., et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. *Proc. Natl. Acad. Sci. USA* 89:12180-12184 (1992).

Larsen, P., et al. *J. Virology* 61:3596 (1987).

Liddington, R., et al. *Nature* 354:278 (1991).

Lin, Y-L., et al. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. *Virology* 187:612 (1992).

McLean, C., et al. Production and characterization of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. *J. Clin. Pathol* 43:488 (1990).

Nakai, Y. *Interviol.* 25:30 (1986).

Olson, C., et al. *Amer. J. Vet. Res.* 21:233 (1960).

Pilacinski, W., et al. *Biotechnology* 2:356 (1984).

Saiki, R. K., et al. *Science* 239:487 (1987).

Seedorf, et al. Human papillomavirus type 16 DNA sequence. *Virology* 145:181-185 (1985).

Shiffman, M. J. *National Cancer Inst.* 84:394 (1992).

Stevens, C., et al. *JAMA* 257:2612 (1987).

Stites, D. Chapter 27 in Basic and Clinical Immunology 3d Ed. H. Fudenberg et al., eds. Los Altos: Lange Medical Publications, 1980.

Summers, M., et al. Texas Agricultural Experiment Station, College Station, Texas. A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures (1987). Bulletin No. 1555.

Zhou, J., et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. *J. Virology* 185:251 (1991).

zur Hausen, H. *Science* 254:1167 (1991).

-23-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: The Government of the United States, as represented by the Secretary of Health and Human Services

(ii) TITLE OF INVENTION: SELF- ASSEMBLING RECOMBINANT PAPILLOMAVIRUS CAPSID PROTEINS

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: KNOBBE, MARTENS, OLSON & BEAR
- (B) STREET: 620 Newport Center Drive, Sixteenth Floor
- (C) CITY: Newport Beach
- (D) STATE: CA
- (E) COUNTRY: USA
- (F) ZIP: 92660

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 07/941,371
- (B) FILING DATE: 03-SEP-1992

- (A) APPLICATION NUMBER: US 08/032,869
- (B) FILING DATE: 16-MAR-1993

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 714-760-0404
- (B) TELEFAX: 714-760-9502

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1517 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Human papillomavirus
- (B) STRAIN: HPV16

-24-

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1518

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | |
|---|-----|
| ATG TCT CTT TGG CTG CCT AGT GAG GCC ACT GTC TAC TTG CCT CCT GTC | 48 |
| Met Ser Leu Trp Leu Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val | |
| 1 5 10 15 | |
| CCA GTA TCT AAG GTT GTA AGC ACG GAT GAA TAT GTT GCA CGC ACA AAC | 96 |
| Pro Val Ser Lys Val Val Ser Thr Asp Glu Tyr Val Ala Arg Thr Asn | |
| 20 25 30 | |
| ATA TAT TAT CAT GCA GGA ACA TCC AGA CTA CTT GCA GTT GGA CAT CCC | 144 |
| Ile Tyr Tyr His Ala Gly Thr Ser Arg Leu Leu Ala Val Gly His Pro | |
| 35 40 45 | |
| TAT TTT CCT ATT AAA AAA CCT AAC AAT AAC AAA ATA TTA GTT CCT AAA | 192 |
| Tyr Phe Pro Ile Lys Lys Pro Asn Asn Asn Lys Ile Leu Val Pro Lys | |
| 50 55 60 | |
| GTA TCA GGA TTA CAA TAC AGG GTA TTT AGA ATA CAT TTA CCT GAC CCC | 240 |
| Val Ser Gly Leu Gln Tyr Arg Val Phe Arg Ile His Leu Pro Asp Pro | |
| 65 70 75 80 | |
| AAT AAG TTT GGT TTT CCT GAC ACC TCA TTT TAT AAT CCA GAT ACA CAG | 288 |
| Asn Lys Phe Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr Gln | |
| 85 90 95 | |
| CGG CTG GTT TGG CCC TGT GTA GGT GTT GAG GTA GGT CGT GGT CAG CCA | 336 |
| Arg Leu Val Trp Ala Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro | |
| 100 105 110 | |
| TTA GGT GTG GGC ATT AGT GGC CAT CCT TTA TTA AAT AAA TTG GAT GAC | 384 |
| Leu Gly Val Gly Ile Ser Gly His Pro Leu Leu Asn Lys Leu Asp Asp | |
| 115 120 125 | |
| ACA GAA AAT GCT AGT GCT TAT GCA GCA AAT GCA GGT GTG GAT AAT AGA | 432 |
| Thr Glu Asn Ala Ser Ala Tyr Ala Ala Asn Ala Gly Val Asp Asn Arg | |
| 130 135 140 | |
| GAA TGT ATA TCT ATG GAT TAC AAA CAA ACA CAA TTG TGT TTA ATT GGT | 480 |
| Glu Cys Ile Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Ile Gly | |
| 145 150 155 160 | |
| TGC AAA CCA CCT ATA GGG GAA CAC TGG GGC AAA GGA TCC CCA TGT ACC | 528 |
| Cys Lys Pro Pro Ile Gly Glu His Trp Gly Lys Gly Ser Pro Cys Thr | |
| 165 170 175 | |
| AAT GTT GCA GTA AAT CCA GGT GAT TGT CCA CCA TTA GAG TTA ATA AAC | 576 |
| Asn Val Ala Val Asn Pro Gly Asp Cys Pro Pro Leu Glu Leu Ile Asn | |
| 180 185 190 | |
| ACA GTT ATT CAG GAT GGT GAT ATG GTT CAT ACT GGC TTT GGT GCT ATG | 624 |
| Thr Val Ile Gln Asp Gly Asp Met Val His Thr Gly Phe Gly Ala Met | |
| 195 200 205 | |

-25-

| | | | | | | | | | | | | | | | | |
|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------|
| GAC Asp 210 | TTT Phe 210 | ACT Thr 210 | ACA Thr 210 | TTA Leu 210 | CAG Gln 215 | GCT Ala 215 | AAC Asn 215 | AAA Lys 215 | AGT Ser 215 | GAA Glu 220 | GTT Val 220 | CCA Pro 220 | CTG Leu 220 | GAT Asp 220 | ATT Ile 220 | 672 |
| TGT Cys 225 | ACA Thr 225 | TCT Ser 225 | ATT Ile 225 | TGC Cys 230 | AAA Lys 230 | TAT Tyr 230 | CCA Pro 230 | GAT Asp 230 | TAT Tyr 235 | ATT Ile 235 | AAA Lys 235 | ATG Met 235 | GTG Val 235 | TCA Ser 240 | GAA Glu 240 | 720 |
| CCA Pro 245 | TAT Tyr 245 | GGC Gly 245 | GAC Asp 245 | AGC Ser 245 | TTA Leu 245 | TTT Phe 245 | TTT Phe 245 | TAT Tyr 250 | TTA Leu 250 | CGA Arg 250 | AGG Arg 250 | GAA Glu 255 | CAA Gln 255 | ATG Met 255 | TTT Phe 255 | 768 |
| GTT Val 260 | AGA Arg 260 | CAT His 260 | TTA Leu 260 | TTT Phe 260 | AAT Asn 260 | AGG Arg 260 | GCT Ala 265 | GGT Gly 265 | ACT Thr 265 | GTT Val 265 | GGT Gly 265 | GAA Glu 270 | AAT Asn 270 | GTA Val 270 | CCA Pro 270 | 816 |
| GAC Asp 275 | GAT Asp 275 | TTA Leu 275 | TAC Tyr 275 | ATT Ile 275 | AAA Lys 280 | GGC Gly 280 | TCT Ser 280 | GGG Gly 280 | TCT Ser 280 | ACT Thr 285 | GCA Ala 285 | AAT Asn 285 | TTA Leu 285 | GCC Ala 285 | AGT Ser 285 | 864 |
| TCA Ser 290 | AAT Asn 290 | TAT Tyr 290 | TTT Phe 290 | CCT Pro 290 | ACA Thr 295 | CCT Pro 295 | AGT Ser 295 | GGT Gly 295 | TCT Ser 295 | ATG Met 300 | GTT Val 300 | ACC Thr 300 | TCT Ser 300 | GAT Asp 300 | GCC Ala 300 | 912 |
| CAA Gln 305 | ATA Ile 305 | TTC Phe 305 | AAT Asn 305 | AAA Lys 310 | CCT Pro 310 | TAT Tyr 310 | TGG Trp 310 | TTA Leu 315 | CAA Gln 315 | CGA Arg 315 | GCA Ala 315 | CAG Gln 315 | GGC Gly 315 | CAC His 315 | AAT Asn 320 | 960 |
| AAT Asn 325 | GGC Gly 325 | ATT Ile 325 | TGT Cys 325 | TGG Trp 325 | GGT Gly 325 | AAC Asn 325 | CAA Gln 330 | CTA Leu 330 | TTT Phe 330 | GTT Val 330 | ACT Thr 330 | GTT Val 335 | GTT Val 335 | GAT Asp 335 | ACT Thr 335 | 1008 |
| ACA Thr 340 | CGC Arg 340 | AGT Ser 340 | ACA Thr 340 | AAT Asn 340 | ATG Met 340 | TCA Ser 345 | TTA Leu 345 | TGT Cys 345 | GCT Ala 345 | GCC Ala 345 | ATA Ile 345 | TCT Ser 350 | ACT Thr 350 | TCA Ser 350 | GAA Glu 350 | 1056 |
| ACT Thr 355 | ACA Thr 355 | TAT Tyr 355 | AAA Lys 355 | AAT Asn 355 | ACT Thr 355 | AAC Asn 360 | TTT Phe 360 | AAG Lys 360 | GAG Glu 360 | TAC Tyr 360 | CTA Leu 365 | CGA Arg 365 | CAT His 365 | GGG Gly 365 | GAG Glu 365 | 1104 |
| GAA Glu 370 | TAT Tyr 370 | GAT Asp 370 | TTA Leu 370 | CAG Gln 375 | TTT Phe 375 | ATT Ile 375 | TTT Phe 375 | CAA Gln 375 | CTG Leu 375 | TGC Cys 375 | AAA Lys 380 | ATA Ile 380 | ACC Thr 380 | TTA Leu 380 | ACT Thr 380 | 1152 |
| GCA Ala 385 | GAC Asp 385 | GTT Val 385 | ATG Met 385 | ACA Thr 390 | TAC Tyr 390 | ATA Ile 390 | CAT His 390 | TCT Ser 390 | ATG Met 395 | AAT Asn 395 | TCC Ser 395 | ACT Thr 395 | ATT Ile 395 | TTG Leu 400 | GAG Glu 400 | 1200 |
| GAC Asp 405 | TGG Trp 405 | AAT Asn 405 | TTT Phe 405 | GGT Gly 405 | CTA Leu 405 | CAA Gln 410 | CCT Pro 410 | CCC Pro 410 | CCA Pro 410 | GGA Gly 410 | GGC Gly 415 | ACA Thr 415 | CTA Leu 415 | GAA Glu 415 | GAT Asp 415 | 1248 |
| ACT Thr 420 | TAT Tyr 420 | AGG Arg 420 | TTT Phe 420 | GTA Val 420 | ACA Thr 425 | TCC Ser 425 | CAG Gln 425 | GCA Ala 425 | ATT Ile 425 | GCT Ala 425 | TGT Cys 425 | CAA Gln 430 | AAA Lys 430 | CAT His 430 | ACA Thr 430 | 1296 |
| CCT Pro 435 | CCA Pro 435 | GCA Ala 435 | CCT Pro 435 | AAA Lys 435 | GAA Glu 435 | GAT Asp 440 | CCC Pro 440 | CTT Leu 440 | AAA Lys 440 | AAA Lys 440 | TAC Tyr 445 | ACT Thr 445 | TTT Phe 445 | TGG Trp 445 | GAA Glu 445 | 1344 |

-26-

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| GTA | AAT | TTA | AAG | GAA | AAG | TTT | TCT | GCA | GAC | CTA | GAT | CAG | TTT | CCT | TTA | 1392 |
| Val | Asn | Leu | Lys | Glu | Lys | Phe | Ser | Ala | Asp | Leu | Asp | Gln | Phe | Pro | Leu | |
| 450 | | | | | | 455 | | | | 460 | | | | | | |
| | | | | | | | | | | | | | | | | |
| GGA | CGC | AAA | TTT | TTA | CTA | CAA | GCA | GGA | TTG | AAG | GCC | AAA | CCA | AAA | TTT | 1440 |
| Gly | Arg | Lys | Phe | Leu | Leu | Gln | Ala | Gly | Leu | Lys | Ala | Lys | Pro | Lys | Phe | |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 | |
| | | | | | | | | | | | | | | | | |
| ACA | TTA | GGA | AAA | CGA | AAA | GCT | ACA | CCC | ACC | ACC | TCA | TCT | ACC | TCT | ACA | 1488 |
| Thr | Leu | Gly | Lys | Arg | Lys | Ala | Thr | Pro | Thr | Thr | Ser | Ser | Thr | Ser | Thr | |
| | | | | 485 | | | | | 490 | | | | | 495 | | |
| | | | | | | | | | | | | | | | | |
| ACT | GCT | AAA | CGC | AAA | AAA | CGT | AAG | CTG | TA | | | | | | | 1518 |
| Thr | Ala | Lys | Arg | Lys | Lys | Arg | Lys | Leu | | | | | | | | |
| | | | 500 | | | | | 505 | | | | | | | | |

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1518 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1518

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ATG | TCT | CTT | TGG | CTG | CCT | AGT | GAG | GCC | ACT | GTC | TAC | TTG | CCT | CCT | GTC | 48 |
| Met | Ser | Leu | Trp | Leu | Pro | Ser | Glu | Ala | Thr | Val | Tyr | Leu | Pro | Pro | Val | |
| 1 | | | | 5 | | | | 10 | | | | | 15 | | | |
| | | | | | | | | | | | | | | | | |
| CCA | GTA | TCT | AAG | GTT | GTA | AGC | ACG | GAT | GAA | TAT | GTT | GCA | CGC | ACA | AAC | 96 |
| Pro | Val | Ser | Lys | Val | Val | Ser | Thr | Asp | Glu | Tyr | Val | Ala | Arg | Thr | Asn | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| | | | | | | | | | | | | | | | | |
| ATA | TAT | TAT | CAT | GCA | GGA | ACA | TCC | AGA | CTA | CTT | GCA | GTT | GGA | CAT | CCC | 144 |
| Ile | Tyr | Tyr | His | Ala | Gly | Thr | Ser | Arg | Leu | Leu | Ala | Val | Gly | His | Pro | |
| | | 35 | | | | 40 | | | | | 45 | | | | | |
| | | | | | | | | | | | | | | | | |
| TAT | TTT | CCT | ATT | AAA | AAA | CCT | AAC | AAT | AAC | AAA | ATA | TTA | GTT | CCT | AAA | 192 |
| Tyr | Phe | Pro | Ile | Lys | Lys | Pro | Asn | Asn | Asn | Lys | Ile | Leu | Val | Pro | Lys | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| | | | | | | | | | | | | | | | | |
| GTA | TCA | GGA | TTA | CAA | TAC | AGG | GTA | TTT | AGA | ATA | CAT | TTA | CCT | GAC | CCC | 240 |
| Val | Ser | Gly | Leu | Gln | Tyr | Arg | Val | Phe | Arg | Ile | His | Leu | Pro | Asp | Pro | |
| 65 | | | | | 70 | | | | 75 | | | | | | 80 | |

-27-

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AAT | AAG | TTT | GGT | TTT | CCT | GAC | ACC | TCA | TTT | TAT | AAT | CCA | GAT | ACA | CAG | 288 |
| Asn | Lys | Phe | Gly | Phe | Pro | Asp | Thr | Ser | Phe | Tyr | Asn | Pro | Asp | Thr | Gln | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| CGG | CTG | GTT | TGG | GCC | TGT | GTA | GGT | GTT | GAG | GTA | GGT | CGT | GGT | CAG | CCA | 336 |
| Arg | Leu | Val | Trp | Ala | Cys | Val | Gly | Val | Glu | Val | Gly | Arg | Gly | Gln | Pro | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| TTA | GGT | GTG | GGC | ATT | AGT | GGC | CAT | CCT | TTA | TTA | AAT | AAA | TTG | GAT | GAC | 384 |
| Leu | Gly | Val | Gly | Ile | Ser | Gly | His | Pro | Leu | Leu | Asn | Lys | Leu | Asp | Asp | |
| | | 115 | | | | | 120 | | | | | 125 | | | | |
| ACA | GAA | AAT | GCT | AGT | GCT | TAT | GCA | GCA | AAT | GCA | GGT | GTG | GAT | AAT | AGA | 432 |
| Thr | Glu | Asn | Ala | Ser | Ala | Tyr | Ala | Ala | Asn | Ala | Gly | Val | Asp | Asn | Arg | |
| | 130 | | | | | 135 | | | | | 140 | | | | | |
| GAA | TGT | ATA | TCT | ATG | GAT | TAC | AAA | CAA | ACA | CAA | TTG | TGT | TTA | ATT | GGT | 480 |
| Glu | Cys | Ile | Ser | Met | Asp | Tyr | Lys | Gln | Thr | Gln | Leu | Cys | Leu | Ile | Gly | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| TGC | AAA | CCA | CCT | ATA | GGG | GAA | CAC | TGG | GGC | AAA | GGA | TCC | CCA | TGT | ACC | 528 |
| Cys | Lys | Pro | Pro | Ile | Gly | Glu | His | Trp | Gly | Lys | Gly | Ser | Pro | Cys | Thr | |
| | | | | 165 | | | | | 170 | | | | | 175 | | |
| AAT | GTT | GCA | GTA | AAT | CCA | GGT | GAT | TGT | CCA | CCA | TTA | GAG | TTA | ATA | AAC | 576 |
| Asn | Val | Ala | Val | Asn | Pro | Gly | Asp | Cys | Pro | Pro | Leu | Glu | Leu | Ile | Asn | |
| | | | 180 | | | | | 185 | | | | | 190 | | | |
| ACA | GTT | ATT | CAG | GAT | GGT | GAT | ATG | GTT | GAT | ACT | GGC | TTT | GGT | GCT | ATG | 624 |
| Thr | Val | Ile | Gln | Asp | Gly | Asp | Met | Val | Asp | Thr | Gly | Phe | Gly | Ala | Met | |
| | | 195 | | | | | 200 | | | | | 205 | | | | |
| GAC | TTT | ACT | ACA | TTA | CAG | GCT | AAC | AAA | AGT | GAA | GTT | CCA | CTG | GAT | ATT | 672 |
| Asp | Phe | Thr | Thr | Leu | Gln | Ala | Asn | Lys | Ser | Glu | Val | Pro | Leu | Asp | Ile | |
| | 210 | | | | | 215 | | | | | 220 | | | | | |
| TGT | ACA | TCT | ATT | TGC | AAA | TAT | CCA | GAT | TAT | ATT | AAA | ATG | GTG | TCA | GAA | 720 |
| Cys | Thr | Ser | Ile | Cys | Lys | Tyr | Pro | Asp | Tyr | Ile | Lys | Met | Val | Ser | Glu | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |
| CCA | TAT | GGC | GAC | AGC | TTA | TTT | TTT | TAT | TTA | CGA | AGG | GAA | CAA | ATG | TTT | 768 |
| Pro | Tyr | Gly | Asp | Ser | Leu | Phe | Phe | Tyr | Leu | Arg | Arg | Glu | Gln | Met | Phe | |
| | | | | 245 | | | | | 250 | | | | | 255 | | |
| GTT | AGA | CAT | TTA | TTT | AAT | AGG | GCT | GGT | ACT | GTT | GGT | GAA | AAT | GTA | CCA | 816 |
| Val | Arg | His | Leu | Phe | Asn | Arg | Ala | Gly | Thr | Val | Gly | Glu | Asn | Val | Pro | |
| | | | 260 | | | | | 265 | | | | | 270 | | | |
| GAC | GAT | TTA | TAC | ATT | AAA | GGC | TCT | GGG | TCT | ACT | GCA | AAT | TTA | GCC | AGT | 864 |
| Asp | Asp | Leu | Tyr | Ile | Lys | Gly | Ser | Gly | Ser | Thr | Ala | Asn | Leu | Ala | Ser | |
| | | 275 | | | | | 280 | | | | | 285 | | | | |
| TCA | AAT | TAT | TTT | CCT | ACA | CCT | AGT | GGT | TCT | ATG | GTT | ACC | TCT | GAT | GCC | 912 |
| Ser | Asn | Tyr | Phe | Pro | Thr | Pro | Ser | Gly | Ser | Met | Val | Thr | Ser | Asp | Ala | |
| | 290 | | | | | 295 | | | | | 300 | | | | | |
| CAA | ATA | TTC | AAT | AAA | CCT | TAT | TGG | TTA | CAA | CGA | GCA | CAG | GGC | CAC | AAT | 960 |
| Gln | Ile | Phe | Asn | Lys | Pro | Tyr | Trp | Leu | Gln | Arg | Ala | Gln | Gly | His | Asn | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | |

-28-

| | |
|---|------|
| AAT GGC ATT TGT TGG GGT AAC CAA CTA TTT GTT ACT GTT GTT GAT ACT | 1008 |
| Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr | |
| 325 330 335 | |
| ACA CGC AGT ACA AAT ATG TCA TTA TGT GCT GCC ATA TCT ACT TCA GAA | 1056 |
| Thr Arg Ser Thr Asn Met Ser Leu Cys Ala Ala Ile Ser Thr Ser Glu | |
| 340 345 350 | |
| ACT ACA TAT AAA AAT ACT AAC TTT AAG GAG TAC CTA CGA CAT GGG GAG | 1104 |
| Thr Thr Tyr Lys Asn Thr Asn Phe Lys Glu Tyr Leu Arg His Gly Glu | |
| 355 360 365 | |
| GAA TAT GAT TTA CAG TTT ATT TTT CAA CTG TGC AAA ATA ACC TTA ACT | 1152 |
| Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr | |
| 370 375 380 | |
| GCA GAC GTT ATG ACA TAC ATA CAT TCT ATG AAT TCC ACT ATT TTG GAG | 1200 |
| Ala Asp Val Met Thr Tyr Ile His Ser Met Asn Ser Thr Ile Leu Glu | |
| 385 390 395 400 | |
| GAC TGG AAT TTT GGT CTA CAA CCT CCC CCA GGA GGC ACA CTA GAA GAT | 1248 |
| Asp Trp Asn Phe Gly Leu Gln Pro Pro Pro Gly Gly Thr Leu Glu Asp | |
| 405 410 415 | |
| ACT TAT AGG TTT GTA ACC CAG GCA ATT GCT TGT CAA AAA CAT ACA CCT | 1296 |
| Thr Tyr Arg Phe Val Thr Gln Ala Ile Ala Cys Gln Lys His Thr Pro | |
| 420 425 430 | |
| CCA GCA CCT AAA GAA GAT GAT CCC CTT AAA AAA TAC ACT TTT TGG GAA | 1344 |
| Pro Ala Pro Lys Glu Asp Asp Pro Leu Lys Lys Tyr Thr Phe Trp Glu | |
| 435 440 445 | |
| GTA AAT TTA AAG GAA AAG TTT TCT GCA GAC CTA GAT CAG TTT CCT TTA | 1392 |
| Val Asn Leu Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu | |
| 450 455 460 | |
| GGA CGC AAA TTT TTA CTA CAA GCA GGA TTG AAG GCC AAA CCA AAA TTT | 1440 |
| Gly Arg Lys Phe Leu Leu Gln Ala Gly Leu Lys Ala Lys Pro Lys Phe | |
| 465 470 475 480 | |
| ACA TTA GGA AAA CGA AAA GCT ACA CCC ACC ACC TCA TCT ACC TCT ACA | 1488 |
| Thr Leu Gly Lys Arg Lys Ala Thr Pro Thr Thr Ser Ser Thr Ser Thr | |
| 485 490 495 | |
| ACT GCT AAA CGC AAA AAA CGT AAG CTG TA | 1517 |
| Thr Ala Lys Arg Lys Lys Arg Lys Leu | |
| 500 505 | |

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

-29-

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Bovine papillomavirus
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: BPV1 N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCGCTGAATT CAATATGGCG TTGTGGCAAC AAGGCCAGAA GCTGTAT

47

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 47 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: BPV1 Y

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCGGTGGTAC CGTGCACTTG ACTTACCTTC TGTTTTACAT TTACAGA

47

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 41 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: HPV16 N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

- 30 -

CCGCTAGATC TAATATGTCT CTTTGGCTGC CTAGTGAGGC C

41

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(vii) IMMEDIATE SOURCE:

(B) CLONE: HPV16 Y

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GCGGTAGATC TACACTAATT CAACATACAT ACAATACTTA CAGC

44

0027

WHAT IS CLAIMED IS:

1. A genetic construct, comprising a papillomavirus L1 conformational coding sequence, inserted into a baculovirus transfer vector, and operatively expressed by a promoter of that vector.
2. The genetic construct of Claim 1, wherein said papillomavirus L1 conformational coding sequence is isolated from a bovine, monkey, or human gene.
3. The genetic construct of Claim 2, wherein said papillomavirus L1 conformational coding sequence is isolated from a wild type HPV16 gene.
4. The genetic construct of Claim 3, wherein said papillomavirus L1 conformational coding sequence is SEQ ID NO:6.
5. The genetic construct of Claim 3, further comprising a papillomavirus L2 coding sequence.
6. A non-mammalian eukaryotic host cell transformed by the genetic construct of any one of Claims 1-5.
7. A method for producing a recombinant papillomavirus capsid protein, assembled into a capsomer structure or a portion thereof, comprising the steps of:
 - cloning a papillomavirus gene that codes for an L1 conformational capsid protein into a transfer vector wherein the open reading frame of said gene is under the control of the promoter of said vector;
 - transferring the recombinant vector into a host cell, wherein the cloned papillomavirus gene expresses said papillomavirus capsid protein; and
 - isolating capsomer structures, comprising said papillomavirus capsid protein, from said cell.
8. The method of Claim 7, wherein the cloned papillomavirus gene consists essentially of the conformational L1 coding sequence, and the expressed protein assembles into capsomer structures consisting essentially of L1 capsid protein.
9. The method of Claim 7, wherein the cloning step further comprises the cloning of a papillomavirus gene coding for L2 capsid protein, whereby said L1 and L2 proteins are coexpressed, and wherein the isolated capsomer structures comprise L1 and L2 capsid proteins;
- provided that said transfer vector is not a vaccinia virus when said host cell is a mammalian cell.
10. The method of Claim 7 or 9 wherein the conformational L1 coding sequence is cloned from a bovine, monkey, or human papillomavirus.

-32-

11. The method of Claim 7 or 9, wherein the conformational L1 coding sequence is cloned from a wild type HPV16 papillomavirus.

12. The method of Claim 11, wherein said conformational L1 coding sequence is SEQ ID NO:6.

5 13. The method of Claim 7, wherein said host cell is an insect cell.

14. The method of Claim 7, wherein said vector is a baculovirus based transfer vector, and the papillomavirus gene is under the control of a promoter that is active in insect cells.

10 15. The method of Claim 7, wherein said recombinant baculovirus DNA is transfected into Sf-9 insect cells.

16. The method of Claim 15, wherein said recombinant baculovirus DNA is co-transfected with wild-type baculovirus DNA into Sf-9 insect cells.

17. The method of Claim 7, wherein said vector is a yeast transfer vector, and the recombinant vector is transfected into yeast cells.

15 18. A virus capsomer structure, or a portion thereof, consisting essentially of papillomavirus L1 capsid protein, produced by the method of Claim 7.

19. A virus capsomer structure, consisting essentially of papillomavirus L1 and L2 capsid proteins, produced by the method of Claim 9.

20 20. A virus capsomer structure according to Claim 18 or 19 wherein said papillomavirus L1 capsid protein is the expression product of an HPV16 L1 DNA cloned from a wild type virus.

21. A virus capsid or a capsomer structure, or a portion thereof, consisting essentially of papillomavirus L1 capsid protein.

25 22. A virus structure according to Claim 21, consisting essentially of wild type HPV16 papillomavirus L1 capsid protein.

23. A virus structure according to any one of Claims 18, 19, 21, or 22, wherein said capsid protein includes an immunogenic conformational epitope capable of inducing neutralizing antibodies against native papillomavirus.

30 24. A virus structure according to Claim 23, wherein said papillomavirus L1 capsid protein is selected from the group consisting of bovine, monkey, or human papillomavirus L1 proteins.

25. A virus structure according to Claim 24, wherein said papillomavirus L1 capsid protein is the expression product of a wild type HPV16 L1 gene.

-33-

26. A virus structure according to Claim 25, wherein said HPV16 L1 gene comprises the sequence of SEQ ID NO:6.

27. A unit dose of a vaccine, comprising a peptide having conformational epitopes of a papillomavirus L1 capsid protein, or L1 protein and L2 capsid proteins, in an effective immunogenic concentration sufficient to induce a papillomavirus neutralizing antibody titer of at least about 10^3 when administered according to an immunizing dosage schedule.

28. The vaccine of Claim 27, wherein said L1 capsid protein is an HPV16 capsid protein.

29. The vaccine of Claim 28, wherein said L1 capsid protein is a wild type HPV16 L1 protein.

30. A method of preventing or treating papillomavirus infection in a vertebrate, comprising the administration of a papillomavirus structure according to Claim 18 or 19 to said vertebrate, according to an immunity-producing regimen.

31. The method of Claim 30 wherein said papillomavirus structure comprises wild type HPV16 L1 capsid protein.

32. A method of preventing or treating papillomavirus infection in a vertebrate, comprising the administration of the papillomavirus structure according to Claim 30 to said vertebrate, according to an immunity-producing regimen.

33. A method of preventing or treating papillomavirus infection in a vertebrate, comprising the administration of the papillomavirus vaccine of Claim 27 to said vertebrate, according to an immunity-producing regimen.

34. The method of Claim 33 wherein said papillomavirus vaccine comprises wild type HPV16 L1 capsid protein.

35. A method for immunizing a vertebrate against papillomavirus infection, comprising administering to said vertebrate a recombinant genetic construct comprising a conformational papillomavirus L1 coding sequence, and allowing said coding sequence to be expressed in the cells or tissues of said vertebrate, whereby an effective, neutralizing, immune response to papillomavirus is induced.

36. A method according to Claim 35, wherein said conformational papillomavirus L1 coding sequence is derived from human papillomavirus HPV16.

37. The method of Claim 36, wherein said human papillomavirus HPV16 is a wild type papillomavirus.

-34-

38. A method of detecting humoral immunity to papillomavirus infection in a vertebrate comprising the steps of:

(a) providing an effective antibody-detecting amount of a papillomavirus capsid peptide having at least one conformational epitope of a papillomavirus capsomer structure;

(b) contacting the peptide of step (a) with a sample of bodily fluid from a vertebrate to be examined for papillomavirus infection, and allowing papillomavirus antibodies contained in said sample to bind thereto, forming antigen-antibody complexes;

(c) separating said complexes from unbound substances;

(d) contacting the complexes of step (c) with a detectably labelled immunoglobulin-binding agent; and

(e) detecting anti-papillomavirus antibodies in said sample by means of the labelled immunoglobulin-binding agent that binds to said complexes.

39. The method of Claim 37, wherein said peptide consists essentially of papillomavirus L1 capsid protein.

40. The method of Claim 38, wherein said peptide consists essentially of the expression product of a human papillomavirus HPV16.

41. The method of Claim 39, wherein said peptide consists essentially of the expression product of a wild type human papillomavirus HPV16 gene.

42. The method of Claim 40, wherein said peptide consists essentially of the expression product of SEQ ID NO:6.

43. A method of detecting papillomavirus in a specimen from an animal suspected of being infected with said virus, comprising

contacting said specimen with antibodies having a specificity to one or more conformational epitopes of the capsid of said papillomavirus, said antibodies having a detectable signal producing label, or being attached to a detectably labelled reagent;

allowing said antibodies to bind to said papillomavirus; and

determining the presence of papillomavirus present in said specimen by means of said detectable label.

44. A method of determining a cellular immune response to papillomavirus in an animal suspected of being infected with said virus, comprising:

-35-

contacting immunocompetent cells of said animal with a recombinant wild type papillomavirus L1 capsid protein, or combined L1 and L2 capsid protein according to Claim 18 or 19; and

assessing cellular immunity to said papillomavirus by means of the proliferative response of said cells to said capsid protein.

45. The method of Claim 44, wherein said recombinant papillomavirus protein is introduced into the skin of said animal.

46. A papillomavirus infection diagnostic kit, comprising capsomer structures consisting essentially of papillomavirus L1 capsid protein, or capsomer structures comprising papillomavirus L1 protein and L2 capsid proteins, or antibodies to either of said capsomers structures, singly or in combination, together with materials for carrying out an assay for humoral or cellular immunity against papillomavirus, in a unit package container.

INTERNATIONAL SEARCH REPORT

Int. Appl. No.

PCT/US 93/08342

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C12N15/37 C12N7/04 C12N15/86 C12N5/10 A61K39/12
G01N33/53 C07K13/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| P, X | <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 89, no. 24, December 1992, WASHINGTON US pages 12180 - 12184 KIRNBAUER, R. ET AL. 'Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic' see the whole document</p> <p style="text-align: center;">--- -/--</p> | 1-46 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 December 1993

Date of mailing of the international search report

18-01-1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 93/08342

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|--|
| P,X | JOURNAL OF VIROLOGY vol. 67, no. 4 , April 1993 pages 1936 - 1944 ROSE, R.C. ET AL. 'Expression of human papillomavirus type 11 L1 protein in insect cells in-vivo and in-vitro assembly of viruslike particles' see the whole document --- | 1-3,6-8, 10, 13-16, 18,21, 27,30, 32,33, 38,39, 43,46 |
| X | JOURNAL OF GENERAL VIROLOGY vol. 72, no. 12 , December 1991 pages 2981 - 2988 XI, S.Z. & BANKS, L.M. 'Baculovirus expression of the human papillomavirus type 16 capsid proteins detection of L1-L2 protein complexes' see the whole document --- | 1-3,5,6, 9-11,13, 16,19,20 |
| X | VIROLOGY vol. 185, no. 1 , November 1991 pages 251 - 257 ZHOU, J. ET AL. 'Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles' see the whole document --- | 7-11, 18-25, 27-37 |
| P,X | WO,A,93 02134 (THE UNIVERSITY OF QUEENSLAND) 4 February 1993 see the whole document ----- | 7-11, 18-46 |

INTERNATIONAL SEARCH REPORT

Information on parent family members

Line Serial Application No

PCT/US 93/08342

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO-A-9302184 | 04-02-93 | NONE | |